Merus (NASDAQ:MRUS) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Merus (NASDAQ:MRUS - Free Report) in a research report sent to investors on Friday, MarketBeat reports. The firm issued an overweight rating and a $91.00 price target on the biotechnology company's stock.

MRUS has been the subject of several other reports. HC Wainwright reiterated a "buy" rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. Citigroup upped their price objective on shares of Merus from $89.00 to $97.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Needham & Company LLC reissued a "buy" rating and issued a $85.00 target price on shares of Merus in a research report on Monday, December 9th. The Goldman Sachs Group started coverage on shares of Merus in a research note on Thursday, November 21st. They set a "buy" rating and a $73.00 price target on the stock. Finally, UBS Group began coverage on shares of Merus in a research note on Thursday, October 24th. They set a "buy" rating and a $72.00 price objective for the company. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $86.08.

Merus Stock Performance

MRUS stock traded down $0.37 during trading on Friday, reaching $40.27. 218,654 shares of the company were exchanged, compared to its average volume of 592,885. Merus has a 52-week low of $37.77 and a 52-week high of $61.61. The company has a market cap of $2.76 billion, a P/E ratio of -10.20 and a beta of 1.11. The stock's 50 day moving average price is $42.10 and its 200 day moving average price is $47.61.

Institutional Trading of Merus

Several institutional investors and hedge funds have recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in Merus during the fourth quarter worth $433,000. Teacher Retirement System of Texas lifted its position in shares of Merus by 28.7% in the 4th quarter. Teacher Retirement System of Texas now owns 14,152 shares of the biotechnology company's stock worth $595,000 after buying an additional 3,155 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Merus by 9.7% in the 4th quarter. Swiss National Bank now owns 93,954 shares of the biotechnology company's stock valued at $3,951,000 after buying an additional 8,300 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Merus by 10.9% in the 4th quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock valued at $337,000 after buying an additional 789 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Merus during the 4th quarter valued at about $347,000. Institutional investors and hedge funds own 96.14% of the company's stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.